ZBH (Zimmer Biomet Holdings) LT-Debt-to-Total-Asset : 0.22 (As of Sep. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Zimmer Biomet Holdings LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Zimmer Biomet Holdings's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.22.

Zimmer Biomet Holdings's long-term debt to total assets ratio declined from Sep. 2023 (0.25) to Sep. 2024 (0.22). It may suggest that Zimmer Biomet Holdings is progressively becoming less dependent on debt to grow their business.

Zimmer Biomet Holdings LT-Debt-to-Total-Asset Historical Data

The historical data trend for Zimmer Biomet Holdings's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zimmer Biomet Holdings LT-Debt-to-Total-Asset Chart

Zimmer Biomet Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.27

0.31

0.23

0.25

0.23

Zimmer Biomet Holdings Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.25	0.23	0.23	0.18	0.22

Zimmer Biomet Holdings LT-Debt-to-Total-Asset Calculation

Zimmer Biomet Holdings's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	5012.6	/	21496.9
	=	0.23

Zimmer Biomet Holdings's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	4859.5	/	21720.3
	=	0.22

Zimmer Biomet Holdings (NYSE:ZBH) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Zimmer Biomet Holdings LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Zimmer Biomet Holdings's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Zimmer Biomet Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zimmer Biomet Holdings Inc (NYSE:ZBH) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ZBH:Mexico ZIM:Germany ZIM:Germany ZBH:Austria

Address

345 East Main Street, Warsaw, IN, USA, 46580

Website

https://www.zimmerbiomet.com

Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.

Executives

Sang Yi	officer: President, Asia Pacific	345 E. MAIN STREET, WARSAW IN 46580
Chad F Phipps	officer: Assoc. Gen. Counsel, Corp. Sec	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Syed A. Jafry	director	345 E. MAIN STREET, WARSAW IN 46580
Sreelakshmi Kolli	director	C/O ALIGN TECHNOLOGY INC., 2820 ORCHARD PARKWAY, SAN JOSE CA 94131
Christopher B Begley	director
Robert Hagemann	director	3 GIRALDA FARMS, MADISON NJ 07940
Michael W Michelson	director	2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
Betsy J Bernard	director	711 HIGH STREET, DES MOINES IA 50392-0300
Arthur J Higgins	director	C/O ZIMMER, INC., P.O. BOX 708, WARSAW IN 46580
Zuilen Wilfred Van	officer: Pres, Europe, M. East & Africa	345 E. MAIN STREET, WARSAW IN 46580
Paul A Stellato	officer: VP, Controller & CAO	C/O XYLEM INC, 1 INTERNATIONAL DRIVE, RYE BROOK NY 10573
Lori Winkler	officer: SVP and CHRO	345 E. MAIN STREET, WARSAW IN 46580
Rachel Ellingson	officer: SVP & CSO	345 E MAIN STREET, WARSAW K7 46580
Bryan C Hanson	director, officer: President and CEO	ZIMMER BIOMET HOLDINGS, 345 E. MAIN STREET, WARSAW IN 46580
Aure Bruneau	officer: Group President	345 E. MAIN STREET, WARSAW IN 46580